# BG00012 and Delay of Disability Progression in Secondary Progressive Multiple Sclerosis

> **NCT02430532** · PHASE3 · TERMINATED · sponsor: **Biogen** · enrollment: 58 (actual)

## Conditions studied

- Multiple Sclerosis, Secondary Progressive

## Interventions

- **DRUG:** dimethyl fumarate
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT02430532
- **Lead sponsor:** Biogen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-05
- **Primary completion:** 2016-01
- **Final completion:** 2016-01
- **Target enrollment:** 58 (ACTUAL)
- **Why stopped:** Sponsor Decision
- **Last updated:** 2017-04-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02430532

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02430532, "BG00012 and Delay of Disability Progression in Secondary Progressive Multiple Sclerosis". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT02430532. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*